Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Contributed by: Business Wire

Logo

Tags

Veterinary

Research

Animal Welfare

Public Policy/Government

Clinical Trials

Biotechnology

Health

Pharmaceutical

Science

AAALAC Accreditation

More Like This

Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

Business Wire associated0

Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform